BofA analyst Tim Anderson raised the firm’s price target on Amylyx (AMLX) to $14 from $10 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated it has a cash runway to the end of 2026. The firm’s higher target reflects changes in estimates, including a lower operating expense forecast in 2026, and updating its base valuation year to 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Halts ORION Program for AMX0035
- Amylyx to discontinue ORION program of AMX0035
- Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals’ Promising Earnings Call Highlights
- Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements